Press

Bioprocess technology company PS Biotech GmbH receives Series A funding following the successful market entry of its Feed Plate®

November 25, 2014

In the spring of 2013, PS Biotech GmbH, a spin-off of RWTH Aachen and the DWI Leibniz Institute for Interactive Materials, received seed funding from High-Tech Gründerfonds to finance the market entry of the Feed Plate®. The Feed Plate® is a tool serving the field of industrial biotechnology, enabling cost-effective screening for the optimal production strain under fed-batch conditions using microtiter plates. Over the last year, PS Biotech could attract a first wave of prominent customers. The company now announces that it has been successful in raising a Series A of financing to accelerate the company’s growth and expand its product portfolio.

Industrial biotechnology aims to develop and implement energy-saving and resource-conserving production processes, with one example being the increased use of microbial production processes in the biotechnological manufacturing of recombinant pharmaceuticals.

At the initial stage of this type of process chains, typically a pool of several thousand clones is being produced in order to identify the optimal strain for future industrial-scale production. However, running these primary screenings on current technology often results in costly misreadings with regards to the efficiency of a strain of bacteria. Consequently, even repeated screening does not necessarily lead to optimal results, as the underlying cause, the wide gap in nutrient conditions in primary screenings as compared to those prevalent in high-volume bioreactors is not being accounted for.

Feed Plate®, PS Biotech’s (www.psbiotech.de) polymer-based feeding system, now enables customers from the fields of biomanufacturing and research to easily and reliably select clones during the primary screening as the tool allows microorganisms to be fed in a controlled manner under fed-batch conditions. The Feed Plate® therefore not only makes selecting the production strain significantly easier, but also ensures the selection process is more reliable than previously available methods. In addition, by using microtiter plates, the Feed Plate® can come into play in high-throughput settings. PS Biotech’s production line was established last year and the Feed Plate® has been available on the market since the beginning of 2014.

Kristina Bruellhoff, managing director and co-founder of PS Biotech GmbH, is pleased with the company’s performance during its first year on the market: “The large amount of positive feedback from our customers testifies that we’re on the right track, acting as proof of the Feed Plate®’s easy handling and the high reproducibility of results: characteristics that other systems on the market are lacking”.

In the meantime, Feed Plate® has become available with a wide range of release rates, substrates and plate formats and was able to generate convincing results in the labs of Henkel, winning an important customer for PS Biotech early on. “The reduction in workload and the associated savings experienced by our customers using the Feed Plate® are substantial,” adds Sebastian Selzer, managing director and co-founder.

“The Feed Plate® offers customers considerably more degrees of freedom in respect to the range of possible nutrients – and thus the range of micro-organisms that can be cultivated. We are delighted that the company is growing rapidly and that it could attract a further investor,” says Dr. Christian Jung of HTGF.

 

About PS Biotech GmbH
PS Biotech GmbH is a bioprocess technology company based in Aachen, founded in 2013 as a spin-off of RWTH Aachen and the DWI Leibniz Institute for Interactive Materials. The company develops, produces and markets polymer-based nutrient release systems for the fed-batch feeding of micro-organisms using microtiter plates. The product portfolio features a wide range of nutrient/ plate combinations, with additional nutrients other than glucose now available. Furthermore, PS Biotech GmbH also offers custom solutions tailor-made to the needs of its customers.

 

Contact:
Kristina Bruellhoff
PS Biotech GmbH
Kackertstr. 4
52072 Aachen
Tel.: 0241-894 6441-10
www.psbiotech.com
info@psbiotech.com

 

About High-Tech Gründerfonds
High-Tech Gruenderfonds invests in young, high potential high-tech start-ups. The seed financing provided is designed to enable start-ups to take an idea through prototyping and to market launch. Typically, High-Tech Gruenderfonds invests EUR 500,000 in the seed stage, with the potential for up to a total of EUR 2 million per portfolio company in follow-on financing. Investors in this public/private partnership include the Federal Ministry of Economics and Technology, the KfW Banking Group, as well as strategic corporate investors including ALTANA, BASF, Bayer, B. Braun, Robert Bosch, CEWE, Daimler, Deutsche Post DHL, Deutsche Telekom, Evonik, media + more venture Beteiligungs GmbH & Co. KG, METRO, Qiagen, RWE Innogy, SAP, Tengelmann and Carl Zeiss. High-Tech Gruenderfonds has about EUR 576 million under management in two funds (EUR 272 million HTGF I, EUR 304 million HTGF II).

 

Contact:

High-Tech Gründerfonds Management GmbH
Dr. Christian Jung
Schlegelstraße 2
53113 Bonn
Tel: + 49 228 / 82 30 01-00
Fax: + 49 228 / 82 30 00-5
info@htgf.de
www.high-tech-gruenderfonds.de

Stay up to date

Subscribe now and receive the latest press releases on investments and other news from High-Tech Gründerfonds. We inform you about important developments at HTGF and provide you with interesting news from our portfolio. Whether it’s a successful exit, a new exciting investment or HR news – you’ll be the first to know!

More Press posts

Press
25. March 2024

Successful exit for HTGF: Novo Nordisk to acquire Cardior Pharmaceuticals

Novo Nordisk will acquire Cardior for up to 1.025 billion Euros in upfront and potential milestone payments. Cardior is a leader in the discovery and development of therapies that target RNA as a means to prevent, repair and reverse diseases of the heart. High-Tech Gründerfonds (HTGF), one of Europe’s leading seed investors, participated in the first financing round in 2017. Bonn, Germany, 25 March 2024 – Novo Nordisk and Cardior Pharmaceuticals today announced that N
 
Press
25. March 2024

Growth push for CI HUB GmbH, Catalyzing Innovation in Content Integration Solutions

Potsdam, 25.03.2024 – Scale Capital, a Danish early stage technology investor with a focus on helping companies accelerate growth in the US market, has announced its investment in CI HUB GmbH, a leading provider of content integration solutions. This significant seven-figure amount from new and existing investors marks a milestone in CI HUB’s journey towards revolutionizing the way corporates and creatives access digital assets and data. CI HUB specializes in developing innovative
 
Press
20. March 2024

graswald.ai raises $3.3M seed round to scale the way brands create 3D content with AI

The Hannover-based start-up has secured seed funding to build Canva for 3D, leveraging generative AI to transform 3D creative processes for 3D product visualisation. Hannover, 20 March 2024 – graswald.ai announced the close of a $3.3 million seed round led by existing investor Lakestar as well as Supernode Global with continued support from existing investor HTGF and further participation from Spatial Computing expert FOV Ventures, Robin Capital, Angel Invest Ventures and Notion Sc